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Introduction: Treatment in moderate or severe Alzheimer’s disease (AD) often involves adding memantine to a
cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and
long-term observational studies supports superiority of memantine-ChEI combination to ChEI monotherapy. We
utilized area-under-the-curve (AUC) analysis to assess six-month cumulative treatment efficacy of memantine-donepezil
combination versus component monotherapies on individual clinical domains and on a composite index.
Methods: Data were pooled from 1,408 individuals with moderate to severe AD from four six-month randomized trials
of memantine monotherapy (n = 570) or add-on therapy (donepezil-only subset: n = 847). AUC changes from baseline
on measures of cognition (SIB), function (ADCS-ADL19), behavior (NPI), global status (CIBIC-Plus), and a composite index
(4D-CI: equally weighted composite of four domain measures) were calculated using the trapezoidal rule and evaluated
via analysis of covariance (ANCOVA) (2-sided-α = 0.05). AUC results were contrasted with visit-by-visit changes
from baseline (“snapshot analysis”), performed using a mixed-effects model with repeated measures (MMRM).
Results: Over the entire six-month period, placebo-only treatment was associated with significant cumulative
worsening on all outcomes. Memantine-donepezil combination showed significantly greater AUC improvements
(point x week) on the SIB, NPI, and CIBIC-Plus than placebo-donepezil (SIB: 68.4 versus 32.0, P = 0.019; NPI: −74.3
versus −28.2, P = 0.003; CIBIC-Plus: −2.5 versus 1.4, P = 0.006) and memantine-only monotherapies (SIB: 68.4 versus
12.0, P <0.001; NPI: −74.3 versus −7.4, P <0.001; CIBIC-Plus: −2.5 versus 2.7, P <0.001), whereas these comparisons
were not significant for the ADCS-ADL19 (memantine-donepezil (1.4) versus placebo-donepezil (−0.9), P = 0.407;
versus memantine-only (−12.2), P = 0.310). Composite index analysis demonstrated significant cumulative advantages
of memantine-donepezil combination (630.0) over placebo-donepezil (344.7, P <0.001) and memantine-only
(152.1, P <0.001) treatments. Combining memantine and donepezil had an additive effect. Compared with AUC analysis,
baseline-to-endpoint change-score analysis underestimated effects of combination therapy, monotherapies, or both.
Conclusions: This large pooled area-under-the-curve analysis of randomized-trial data in moderate to severe AD
provides ecologically valid support that adding memantine to stable donepezil results in overall clinical benefits
that are additive compared with individual monotherapies, continue to accumulate through six-month treatment,
and are at least 50% greater than those of monotherapies.* Correspondence: atria@cpmcri.org
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It has been more than two decades since the first cholin-
esterase inhibitor (ChEI) was approved for Alzheimer’s dis-
ease (AD) dementia and more than a decade since an
agent from a distinct pharmacological class of treatment —
memantine, the uncompetitive N-methyl-D-aspartate
(NMDA) receptor antagonist [1]— was approved. In the
meantime, a string of promising drug candidates have failed
in clinical trials, which brought into question the validity of
assumptions regarding the pathophysiology of AD, risk fac-
tors, and disease models, as well as the methodology of clin-
ical research. While promising therapeutics are still being
developed, the current treatment paradigm remains un-
changed: monotherapy with a ChEI (donepezil, galantamine,
or rivastigmine [2]) in the earlier stages of AD with addition
of memantine [3] in the moderate or severe stages.
Preclinical evidence suggests that the mechanisms of
action of ChEIs and memantine are complementary [4],
and the preponderance of clinical evidence —from ran-
domized placebo-controlled trials (RCTs) [5-8], post hoc
pooled analyses [9], and real-world observational cohort
effectiveness studies [10-12]— indicates that memantine-
ChEI combination therapy is superior to monotherapy
with either drug or drug class.
However, AD is characterized by diverse symptoms that
can vary highly during the natural course of the disease
and from patient to patient [10,13-15], which makes the
usual ‘snapshot’ assessment of efficacy (mean baseline-to-
endpoint change in one or two clinical domains) a sub-
optimal approach. Such an analysis (1) simplifies disease
trajectory and response to treatment as linear phenomena,
(2) ignores the complexity of the AD syndrome, and (3)
does not take into account patient-to-patient variability
in clinical trajectories, including the variability in emer-
gence, duration, and severity of symptoms [16-18]. In
other words, a typical protocol-based efficacy assessment
in AD does not provide much insight about the cumula-
tive effects of treatment, thereby neglecting information
of potentially great value to researchers, practicing phy-
sicians, and caregivers.
The area under the curve (AUC) analysis can be a sim-
ple method of capturing clinically relevant information
associated with chronic conditions [19,20], but it has not
gained traction among the AD clinical trialist community.
To the best of our knowledge, there is only one published
AD article that applied this method, in a post hoc fashion,
with the stated objective ‘to describe and demonstrate use
of a pooled index and AUC calculations to analyze the
trial data from a randomized controlled trial’ [17]. More
recently, we advocated for the AUC method as a prag-
matic and potentially highly useful approach in analyzing
AD trials, particularly those that aim to assess cumulative,
non-linear benefits [16] that may also be ‘disease-course
modifying’ [21].Therefore, in order to provide a more ecologically valid
assessment of mono- versus combination-therapy in AD,
we conducted a pooled post hoc AUC analysis of data
from four six-month randomized trials in which indi-
viduals with moderate to severe AD were treated with
placebo, monotherapy (memantine or placebo-donepezil),
or combination therapy (memantine-donepezil). Lastly,
we assessed whether the combined effect of memantine
and donepezil is additive or synergistic by examining




The four trials pooled in this analysis were all six-month,
randomized (1:1), multicenter, parallel-group, double-blind
studies of patients with moderate to severe AD (combined
protocol-specified Mini Mental State Exam (MMSE)
score range: 3 to 14) treated with placebo or memantine
(immediate-release formulation, 10 mg/b.i.d. [6-8], or
extended-release formulation, 28 mg q.d. [5]) on a back-
ground of no ChEI therapy [6,8], stable donepezil therapy
[7], or therapy with stable doses of any ChEI [5] (Table 1).
Study sample
The pooled data were allocated based on the type of treat-
ment the participants had received (Table 1) to one of four
treatment groups: placebo (PBO), memantine only (MEM),
placebo-donepezil (PBO-DON), and memantine-donepezil
(MEM-DON). In order to limit heterogeneity and allow for
better comparison with a previous pooled analysis [9], data
from participants who were taking a ChEI other than
donepezil at baseline were excluded.
Efficacy outcome measures
Assessment tools in this analysis comprised the mea-
sures of cognition, function, behavior (neuropsychiatric
symptoms), and global clinical status utilized in the indi-
vidual trials. Additionally, to test the hypothesis that ro-
bust multi-domain benefits accumulate over the course of
six months of combination treatment and that they exceed
those associated with monotherapy, we created a compos-
ite index consisting of the four principle clinical domains
(cognition, function, behavior, global status).
The cognitive outcome measure was the Severe Impair-
ment Battery (SIB) [22,23], a 40-item, 100-point scale de-
signed to assess cognitive performance in patients with
moderate to severe AD, in which lower scores indicate
greater impairment. Daily function was assessed using the
19-item AD Cooperative Study – Activities of Daily Living
scale (ADCS-ADL19) [24,25], a 54-point instrument de-
signed to assess functional abilities in patients with mod-
erate to severe AD; lower ADCS-ADL19 scores indicate
greater impairment. Behavioral symptoms were assessed
Table 1 Summary of patient characteristics and clinical outcomes in memantine trials in moderate to severe AD
Parameter MRZ-90001-9605 [6] MEM-MD-01 [8] MEM-MD-02 [7] MEM-MD-50 [5]
MEM monotherapy MEM monotherapy MEM added to DON MEM added to ChEI
10 mg b.i.d. IR 10 mg b.i.d. IR 10 mg b.i.d. IR 28 mg q.d. ER


















Age, yearsa 76.3 ± 7.8 75.9 ± 8.4 78.3 ± 7.6 78.1 ± 8.2 75.5 ± 8.7 75.5 ± 8.4 76.8 ± 7.8 76.2 ± 8.4
Women, number (%) 79 (63) 91 (72) 121 (70) 129 (72) 134 (67) 128 (63) 243 (72) 244 (72)
White, number (%) 115 (91) 112 (89) 141 (82) 142 (80) 186 (92) 182 (90) 312 (93) 324 (95)
Weight, kga 66.1 ± 14.1 64.5 ± 12.4 65.9 ± 12.8 64.5 ± 13.5 66.2 ± 14.1 70.5 ± 14.3 64.6 ± 13.3 65.1 ± 12.8
MMSE scorea 8.1 ± 3.6 7.7 ± 3.7 10.3 ± 3.1 10.0 ± 2.8 10.2 ± 3.0 9.9 ± 3.1 10.6 ± 2.9 10.9 ± 2.9
MMSE rangeb 1 to 14 5 to 16 5 to 16 3 to 17
Concomitant anti-dementia
treatment





Duration, weeks 28 24 24 24
Score changes from baseline
at study endpoint (LOCF)a
















P valuec <0.001 0.62 <0.001 0.001
















P valuec 0.022 0.28 0.028 0.18
















P valuec 0.37 0.96 0.002 0.005
















P valuee 0.06 0.18 0.027 0.008
aMean ± SD; bMMSE range shown is actual, which may differ from protocol-specified range; cP values for continuous variables (ADCS-ADL19, SIB, NPI) were generated
using ANCOVA models for all trials except for MRZ-90001-9605, in which the Wilcoxon-Mann–Whitney test was used. For the categorical variable (CIBIC-Plus), P values
were generated using a Cochran-Mantel-Haenszel test, except for the MRZ-90001-9605 trial, in which Wilcoxon-Mann–Whitney test was used; dCIBIC-Plus rating reflects
a change from baseline; therefore, endpoint values are used; eP values for CIBIC-Plus are based on the CMH test. AD, Alzheimer’s disease; ADCS-ADL19, 19-item Alzheimer’s
Disease Cooperative Study – Activities of Daily Living scale; ANCOVA, analysis of covariance; b.i.d., twice daily; ChEI, cholinesterase inhibitor; CIBIC-Plus, Clinician’s Interview-
Based Impression of Change – Plus Caregiver Input scale; DON, donepezil; ER, extended release; IR, immediate release; MEM, memantine; MMSE, Mini-Mental
State Examination; NPI, Neuropsychiatric Inventory; OC, observed cases; PBO, placebo; q.d., once daily; SD, standard deviation; SIB, Severe Impairment Battery.
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12-item, 144-point scale used to assess the frequency and
severity of behavioral symptoms in patients with demen-
tia; higher NPI scores indicate greater impairment. Global
clinical status was assessed using the Clinician’s Interview-
Based Impression of Change Plus Caregiver Input (CIBIC-
Plus) [27], a tool that incorporates patient examination
and caregiver interviews by raters who are blinded to data
from other rating instruments. Scores reflect a change
from baseline, and are rated on a scale from 1 (marked
improvement) to 7 (marked worsening), with 4 indicating
no change. Severity at baseline is assessed by means of theClinician’s Interview-Based Impression of Severity (CIBIS),
in which disease severity is quantified using a 7-point
scale, with 7 denoting the greatest severity. Finally, we
constructed a Z-score-type four-domain composite index
measure (4D-CI) by equally weighting all outcome mea-
sures (SIB, ADCS-ADL19, NPI, and CIBIS) based on their
baseline score distribution.
Data analysis
Baseline demographic and clinical characteristics
Age, race, sex, weight, and MMSE score at baseline
were assessed using summary statistics (mean ± SD) and
Atri et al. Alzheimer's Research & Therapy  (2015) 7:28 Page 4 of 12compared by means of analysis of variance (ANOVA) (con-
tinuous variables) or a chi-squared test (dichotomous vari-
ables). No adjustments for multiple comparisons were made
(that is, each variable was considered independently).
Baseline-to-endpoint efficacy analysis (‘snapshot’)
Since three of the four pooled studies were 24 weeks in
duration (Table 1) [5,7,8], endpoint was defined as the
24-week post-baseline visit. In the fourth trial, which was
28 weeks in duration [6], 24-week scores were imputed
based on the assumption of linear change between Week
28 and the most recent prior visit. Baseline-to-endpoint
changes for the SIB, ADCS-ADL19, NPI, and 4D-CI, as
well as endpoint values for CIBIC-Plus, were estimated
based on observed cases, using a mixed-effects model with
repeated measures (MMRM). Interactions between base-
line characteristics (age, race (white, non-white), weight,
and MMSE score) and treatment groups were performed
by means of a separate MMRM analysis and included in
the final model if significant (α = 0.10, two-sided). No ad-
justments were made for multiple comparisons between
different measures, − that is, each measure was considered
independently (α = 0.05, two-sided).
Area under the curve analysis
For each patient, the AUC for changes on the SIB,
ADCS-ADL19, NPI, CIBIC-Plus, and 4D-CI was calculated
for all available time intervals (Weeks 0 to 24, 4 to 24, andTable 2 Baseline characteristics of pooled populations
Parameter Statistic/Category PBO
Age, years number 281
Range 51 to 97
Mean ± SD 77.3 ± 7.8
P-value 0.0378b
Sexa Men 91 (32)
Women 190 (68)
P-value 0.3482c
Racea Non-white 40 (14)
White 241 (86)
P-value <0.0001b
Weight, kg Number 281
Range 39 to 106
Mean ± SD 65.9 ± 13.3
P-value 0.0049b
MMSE score Number 281
Range 1 to 16
Mean ± SD 9.3 ± 3.5
P-value <0.0001b
aData are presented as number (%); banalysis of variance (ANOVA); cChi-squared tes
DON, donepezil; MEM, memantine; MMSE, Mini Mental State Exam; PBO, placebo; Sso on), using the trapezoidal rule. The NPI was not ad-
ministered at Week 4; therefore, Week 4 NPI data were
imputed from the line connecting baseline and Week 8 as-
sessments. For each treatment interval, patient-level data
were combined and treatment groups were compared by
means of an analysis of covariance (ANCOVA) model
with treatment group and baseline value in the model
(α = 0.05, two-sided). Cumulative improvement or decline
was assessed against zero AUC. In addition, the potential
synergism was assessed by adding the term for memantine
x donepezil interaction in the model (α = 0.10, two-sided).
No adjustments were made for multiple comparisons– that
is, each measure was considered independently.
Results
Pooled trials and study populations
Characteristics of the four trials used to create data pools,
including protocol-specified outcomes, are summarized in
Table 1.
Baseline characteristics of the four study populations
used in this analysis are shown in Table 2. The statistically
significant between-group differences in age, weight,
MMSE score, and race distribution were small in mag-
nitude and relatively clinically insignificant. For example,
the mean baseline MMSE score in the MRZ-90001-9605
study (comparing placebo and memantine) was ap-
proximately two points lower than in the other studies,
while the mean age at baseline in the MEM-MD-01MEM PBO-DON MEM-DON
289 418 429
50 to 95 50 to 97 50 to 95
77.2 ± 8.3 76.1 ± 8.3 75.8 ± 8.2
79 (27) 130 (31) 144 (34)
210 (73) 288 (69) 285 (66)
47 (16) 24 (6) 24 (6)
242 (84) 394 (94) 405 (94)
285 418 429
31 to 110 39 to 128 36 to 113
64.4 ± 13.0 65.4 ± 13.9 67.9 ± 14.0
289 418 429
2 to 15 3 to 15 3 to 16
9.0 ± 3.4 10.6 ± 2.9 10.6 ± 3.0
t.
D, standard deviation.
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proximately two years older than in the other studies.
In the Snapshot analysis that adjusted for baseline char-
acteristics, the treatment-by-baseline age interaction was
statistically significant for all four outcomes (P <0.05 for
each); all other treatment-by-baseline characteristic terms
were not significant and were removed from the final
model. Analyses with and without adjustments for base-
line characteristics produced nearly identical results; the
adjusted results are presented in Figures 1, 2, 3, 4 and 5.
Efficacy
Cognition (SIB)
In the Snapshot analysis (Figure 1A), the MEM-DON
group significantly outperformed the PBO group and the
monotherapy groups (MEM and PBO-DON) at study
endpoint (all: P <0.001). Additionally, both monotherapy
groups significantly outperformed the PBO group (P <0.001
each), with the PBO-DON group also performingFigure 1 Cognition (SIB): Snapshot and AUC analysisa. aIn panels A and
statistical comparisons are made with respect to no change from baseline
corrected for interval duration (four or six weeks). *P <0.05 **P <0.01 ***P <0.0
placebo added to background donepezil treatment; SE, standard error of thesignificantly better than the MEM group (P <0.001).
Only the MEM-DON treatment group was associated
with an improvement over baseline (P <0.001).
The AUC approach corroborated the main snapshot
findings, but it also suggests that the snapshot analyses
underestimated the effect of monotherapies on the SIB
versus baseline and exaggerated any potential difference
between monotherapies (Figure 1A and B). The AUC ap-
proach also revealed that, at the last interval in the study
(Week 18 to 24), MEM-DON was the only group still ac-
cumulating treatment benefits (P <0.0001) (Figure 1D).
While this could be inferred from visit-by-visit data
(Figure 1C), it would be more difficult to quantify it
using just the snapshot approach.
Function (ADCS-ADL19)
In the Snapshot analysis, the MEM-DON group signifi-
cantly outperformed the PBO group (P <0.0001), the MEM
group (P = 0.001), and the PBO-DON group (P = 0.0203) atB, statistical comparisons are made between groups; in C and D,
(zero change from baseline) and zero AUC, respectively. bAUC values
01. AUC, area under the curve; LS, least squares; PBO, placebo; PBO-DON,
mean; SIB, Severe Impairment Battery.
Figure 2 Function (ADCS-ADL19): Snapshot and AUC analysis
a. aIn panels A and B, statistical comparisons are made between groups; in C and
D, statistical comparisons are made with respect to no change from baseline (zero change from baseline) and zero AUC, respectively. bAUC
values corrected for interval duration (four or six weeks). *P <0.05 **P <0.01 ***P <0.001. ADCS-ADL19, 19-item Alzheimer’s Disease Cooperative
Study – Activities of Daily Living scale; AUC, area under the curve; LS, least squares; PBO, placebo; PBO-DON, placebo added to background
donepezil treatment; SE, standard error of the mean.
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tically significant baseline-to-endpoint decline (Figure 2C).
In contrast, the only significant differences in the Week 0
to 24 AUC analysis were between MEM-DON versus
the PBO group and between the PBO-DON and the PBO
groups. In addition, neither the MEM-DON nor the PBO-
DON groups were associated with a cumulative decline
across the entire trial (MEM-DON, P = 0.769; PBO-DON,
P = 0.62). However, the MEM-DON was the only group
that did not accumulate decline in the last treatment
interval (Week 18 to 24, P = 0.369; Figure 2D).
Behavior (NPI)
In the Snapshot analysis of baseline-to-endpoint changes,
the MEM-DON group significantly outperformed the
PBO group (P <0.0001), the MEM group (P = 0.0002), and
the PBO-DON group (P = 0.0007), but there were no
significant differences between the two monotherapiesor monotherapies versus placebo (Figure 3A). In addition,
MEM-DON was the only treatment group associated with
a statistically significant improvement over baseline at
endpoint (P <0.0001) (Figure 3C).
The Week 0 to 24 AUC analysis largely corroborated
those findings, while also revealing that the PBO-DON
group performed significantly better than the PBO group
and that both MEM-DON and PBO-DON groups demon-
strated a significant cumulative improvement in behavior
over the 24-week span (MEM-DON, P <0.0001; PBO-DON,
P= 0.005) (Figure 3B). Additionally, MEM-DON was the
only group that continued to accumulate treatment benefits
at the Week 18 to 24 interval (P <0.0001) (Figure 3D).
Global clinical status (CIBIC-plus)
Compared to the AUC approach, the Snapshot approach
underestimated the effect of six-month combination
therapy on global clinical status. In the Snapshot analysis,
Figure 3 Behavior (NPI): Snapshot and AUC analysisa. aIn panels A and B, statistical comparisons are made between groups; in C and D,
statistical comparisons are made with respect to no change from baseline (zero change from baseline) and zero AUC, respectively. bAUC values
corrected for interval duration (four or six weeks). *P <0.05 **P <0.01 ***P <0.001. AUC, area under the curve; LS, least squares; MEM, memantine;
MEM-DON, memantine added to background donepezil treatment; NPI, Neuropsychiatric Inventory; PBO, placebo; PBO-DON, placebo added to
background donepezil treatment; SE, standard error of the mean.
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PBO group (P <0.0001), the MEM group (P = 0.008), and
the PBO-DON group (P = 0.0025) (Figure 4A). There were
no significant differences between monotherapy groups,
but they both significantly outperformed the PBO group
(P <0.001 each) (Figure 4A), and MEM-DON was the only
group that did not demonstrate a significant baseline-to-
endpoint decline (Figure 4C). In the Week 0 to 24 AUC
analysis, the MEM-DON group also significantly outper-
formed the other three groups, and the PBO-DON group
also performed significantly better than the PBO group
(Figure 4B). However, MEM-DON was the only treatment
that was associated with a cumulative improvement across
the entire trial (P = 0.0097) (Figure 4B) and was also the
only group in the Week 18 to 24 interval that did not
accumulate decline (P = 0.912; Figure 4D).Composite index measure (4D-CI)
In the Snapshot analysis, the MEM-DON group signifi-
cantly outperformed the monotherapy groups (MEM and
PBO-DON) and the PBO group (all: P <0.0001) at end-
point (Figure 5A). Additionally, the monotherapy groups
did not differ significantly from each other, but both sig-
nificantly outperformed the PBO group (P <0.0001 each)
(Figure 5A). MEM-DON was the only active treatment
group that demonstrated a significant baseline-to-endpoint
improvement (P <0.0001) (Figure 5C).
In the AUC analysis, improvement on the composite
measure of efficacy for the MEM-DON group was signifi-
cantly greater across the entire trial than the improve-
ments observed in the monotherapy groups (MEM-DON
versus MEM, P <0.0001; MEM-DON versus PBO-DON,
P = 0.0003) (Figure 5B). In addition, all three active-
Figure 4 Global Clinical Status (CIBIC-Plus): Snapshot and AUC analysisa. aIn panels A and B, statistical comparisons are made between groups;
in C and D, statistical comparisons are made with respect to no change from baseline (zero change from baseline) and zero AUC, respectively. bAUC
values corrected for interval duration (four or six weeks). *P <0.05 **P <0.01 ***P <0.001. AUC, area under the curve; CIBIC-Plus, Clinician’s Interview-Based
Impression of Change – Plus Caregiver Input; LS, least squares; MEM, memantine; MEM-DON, memantine added to background donepezil treatment;
PBO, placebo; PBO-DON, placebo added to background donepezil treatment; SE, standard error of the mean.
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showed a significant cumulative decline (Figure 5B).
The AUC difference between monotherapy groups was
not statistically significant (P = 0.0747). In the final
study interval (Week 18 to 24), MEM-DON and PBO-
DON groups continued to accumulate benefits (MEM-
DON, P <0.0001; PBO-DON, P = 0.0013; Figure 5D).
Relative improvements versus placebo
Compared with cumulative decline in the PBO group,
the MEM-DON group was associated with relative AUC
improvements ranging from 104.4% (ADCS-ADL19) to
459.3% (4D-CI) (Table 3). On the ADCS-ADL19, cumu-
lative decline observed in the MEM and PBO-DON groups
was 62.6% and 71.1% smaller, respectively, than the decline
in the PBO group; a similar effect was observed for the
CIBIC-Plus (Table 3). In addition, for all five efficacy
parameters, absolute improvement over placebo in theMEM-DON group versus the sum of improvements in
the MEM and PBO-DON groups indicated that the clin-
ical effect of combining memantine and donepezil was
additive, not synergistic (SIB (point x week): 118.8 ver-
sus 135.2, memantine x donepezil interaction: P = 0.387;
ADCS-ADL19, 34.2 versus 43.8, P = 0.370; NPI: 96.8 versus
79.4, P = 0.322; CIBIC-Plus: 8.1 versus 8.6, P = 0.685;
4D-CI: 805.4 versus 847.4, P = 0.972).
Discussion
This pooled AUC analysis of data from over 1,400 pa-
tients from four RCTs in moderate to severe AD provides
robust support for the view that, over the course of six
months, adding memantine to stable donepezil therapy
results in cumulative multi-domain benefits that are su-
perior to monotherapy with either drug. In addition, our
data suggest that, for all four clinical domains examined
(cognition, daily functioning, behavior, global clinical status),
Figure 5 4D-CI Composite Index: Snapshot and AUC analysisa. aIn panels A and B, statistical comparisons are made between groups; in C and
D, statistical comparisons are made with respect to no change from baseline (zero change from baseline) and zero AUC, respectively. bAUC values
corrected for interval duration (four or six weeks). **P <0.01 ***P <0.001. 4D-CI, four-dimensional composite index; AUC, area under the curve; LS, least
squares; MEM, memantine; MEM-DON, memantine added to background donepezil treatment; PBO, placebo; PBO-DON, placebo added to background
donepezil treatment; SE, standard error of the mean.
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benefits of combination or monotherapy, or both, compared
with the assessment of cumulative effects using the AUC
method. Finally, the results indicated that benefits of com-
bination therapy, compared to individual monotherapies,
are additive, but not synergistic.
Results from both the primary AUC analysis and the
secondary comparative MMRM analysis extend previous
evidence from randomized trials that adding memantine
to stable background donepezil treatment in patients with
moderate or severe AD is associated with significant clin-
ical benefits over adding placebo [5,7] by demonstrating
that memantine-donepezil combination is superior to
both component monotherapies, and that, as expected,
donepezil and memantine monotherapies are superior
to no active treatment (placebo) [9,28]. Those findings
are also in agreement with long-term, prospective obser-
vational cohort studies (three to four years or longer) thatsupport the benefits of ChEI-memantine combination
therapy over monotherapy, and monotherapy over no
treatment [9,28,29]. Our analysis quantifies the cumula-
tive aspect of the combination therapy benefits and sug-
gests that they continue accumulating through the end of
the six-month study period, both in individual domains,
and overall, as measured using the 4D-CI.
The results also extend previous findings by quantifying,
in a readily interpretable manner for clinicians and care-
givers, the magnitude of treatment benefits over the ab-
sence of active treatment (Table 3). For example, it is
clinically useful to be able to discuss with patients and care-
givers that, on average, over a period of six months, patients
who were treated with placebo continued to decline overall
on a composite measure of cognition, function, behavior
and global status, whereas, relatively speaking, those treated
with the memantine-donepezil combination accrued bene-
fits of up to 450%, depending on the clinical characteristic
Table 3 AUC improvements relative to placebo
Assessment Parameter PBO MEM PBO-DON MEM-DON
number = 281 number = 289 number = 418 number = 429
SIB AUC0-24
a −51.4 ± 10.9 4.9 ± 10.5 27.5 ± 8.6 67.4 ± 8.3
│Xb - PBO│c 0 56.3* 78.9*** 118.8***
│Xb - PBO│/│PBO│, % - 109.6 153.5 231.1
ADCS-ADL19 AUC0-24
a −32.7 ± 6.4 −12.2 ± 6.2 −9.5 ± 5.0 1.4 ± 4.9
│Xb - PBO│c 0 20.5 23.3* 34.2***
│Xb - PBO│/│PBO│, % - 62.6 71.1 104.4
NPId AUC0-24
a 22.4 ± 12.2 −7.3 ± 11.8 −27.2 ± 9.7 −74.3 ± 9.4
│Xb - PBO│c 0 29.8 49.6** 96.8***
│Xb - PBO│/│PBO│, % - 132.5 221.0 431.2
CIBIC-Plus AUC0-24
a 6.0 ± 1.1 2.0 ± 1.0 1.4 ± 0.9 −2.1 ± 0.8
│Xb - PBO│c 0 4.0 4.6* 8.1***
│Xb - PBO│/│PBO│, % - 65.9 76.2 135.6
4D-CI AUC0-24
a −175.4 ± 63.7 152.1 ± 61.5 344.7 ± 50.4 630.0 ± 49.0
│Xb - PBO│c 0 327.4** 520.0*** 805.4***
│Xb - PBO│/│PBO│, % - 186.7 296.6 459.3
aMean ± SE (point x week); bany active treatment group; cmean (point x week); dfor NPI, lower score indicates improvement. *P <0.05; **P <0.01; ***P <0.001.
4D-CI, four-dimensional composite index; ADCS-ADL19, 19-item Alzheimer’s Disease Cooperative Study – Activities of Daily Living scale; AUC, area under the curve;
CIBIC-Plus, Clinician’s Interview-Based Impression of Change – Plus Caregiver Input; MEM, memantine; MEM-DON, memantine added to background donepezil
treatment; NPI, Neuropsychiatric Inventory; PBO, placebo; PBO-DON, placebo added to background donepezil treatment; SE, standard error of the mean; SIB,
Severe Impairment Battery.
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background treatment with donepezil could improve an
overall cumulative benefit by approximately 50% (Table 3).
While the AUC and 4D-CI results clearly support the
ordinal benefits of monotherapy and add-on combination
therapy relative to the detrimental effects of non-drug
treatment (that is, treatment with placebo only), the bene-
fits of monotherapies relative to each other are less differ-
entiated. In the snapshot baseline-to-endpoint and the
visit-by-visit changes from baseline analyses, donepezil-
placebo treatment produced significantly larger effects
on the SIB (cognitive measure) than memantine mono-
therapy (Figure 1). In contrast, no difference was observed
in the 0 to 24 week AUC analysis and a small, but signifi-
cant, difference in favor of donepezil-placebo treatment
was observed in the 18 to 24 week-interval weekly AUC
analysis. These results could indicate a signal of greater
relative effect on cognition for donepezil compared to
memantine monotherapy. However, there is a caveat to
this observation due to the clinically small but statistically
significant differences in baseline MMSE score and age,
observed in the two trials of memantine monotherapy:
the mean baseline MMSE score in the MRZ-90001-9605
study was approximately two points lower than in the
other studies, and the mean age at baseline in the MEM-
MD-01 study was approximately two years older than
the other studies. While the analyses adjusted for statis-
tically significant baseline differences and baseline-by-age interactions, these clinically small differences preclude
us from making final conclusions regarding any potential
differential cognitive effect of donepezil versus memantine
monotherapy in this population.
Assessments based on changes from baseline at a single
time point are bound to obscure the longitudinal aspects
of treatment effects and ignore most information re-
garding the emergence, onset, duration, and variability
of symptoms or disease characteristics [19]. In our analysis,
for example, score or score change trajectories over time
for all four outcome measures were not linear (Figures 1C,
2C, 3C and 4C), and a simple baseline-to-endpoint assess-
ment would falsely assume that they were, thereby leading
to potentially inaccurate estimates of treatment effects.
This suggests that the AUC method would be a more
robust tool for analyzing non-linear clinical data. In
addition, the AUCs are intuitive, straightforward to imple-
ment, and maintain the direction of improvement of each
individual scale. When calculated at the patient level, they
represent each individual’s summary of change for a given
period of time (as opposed to change at a given time point)
and can be treated as raw data for statistical analyses.
Similarly, use of composite indices may be associated
with several advantages compared with analyzing data
from different clinical domains separately. For example, a
pre-specified composite index could be a more ecologic-
ally valid [30] way of capturing change in a condition as
complex as AD [15], and it could simplify the problem of
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tools designed to assess individual clinical domains. This,
in turn, could reduce the need for multiple hypothesis
testing: researchers could prospectively create a composite
index that best addresses their key experimental question
and only perform secondary analyses for questions of
secondary importance.
Study strengths
This analysis represents the largest pool to date of patients
with moderate to severe Alzheimer’s dementia (N = 1,408)
treated in rigorous RCTs. The study also utilized robust
analytics methods (MMRM, ANCOVA) to compare the
Snapshot (baseline-to-endpoint) and AUC approaches.
The AUC method has the potential to ‘smooth the data’ of
patients whose visit-by-visit scores are prone to variations,
thereby potentially increasing the signal-to-noise ratio.
Additionally, combining the AUC approach with the
4D-CI extends the smoothing effect across four critical
clinical domains and allows for integration of various
clinical assessments over time into a single numerical
value. By potentially lowering noise stemming from vari-
ance, such a composite representation would have the
advantage of capturing treatment-related effects more
robustly, and with higher power. Finally, the relative ef-
fect estimates (Table 3) allow for intuitive and meaning-
ful interpretations of clinical-trial data.
Study limitations
Excluding patients with background ChEI treatment
other than donepezil may reduce external validity and
generalizability of results. Another potential limitation,
which applies to the individual pooled trials as well, in-
volves use of MMSE as a key criterion for study enroll-
ment. That measure assesses cognition only —just one
of several AD domains— and it does so in a limited
fashion, particularly in patients with high education and
intellectual abilities. Finally, in clinical practice, patients
are usually treated for periods longer than the six-month
duration of trials pooled for the purpose of this analysis,
which emphasizes the necessity of obtaining Level II evi-
dence from long-term observational clinical cohort studies
in order to better delineate the long-term risk–benefit cal-
culus of therapies to patients and to society, and to better
guide therapeutic discovery efforts [10,28,29].
Clinical recommendations and future directions
Based on these results, which add to the preponderance
of clinical evidence [5-12] that memantine add-on-to-
donepezil/ChEI combination therapy is superior to compo-
nent monotherapies and that non-treatment is associated
with significant decline over six months, it is our clinical
recommendation that, barring any contraindication, all in-
dividuals in the moderate or severe stages of AD dementiareceive combination treatment. However, this study does
not inform regarding when anti-AD medications should be
stopped; there is a dearth of data to inform regarding this
very important aspect of AD management that requires
further study.
Finally, a recent FDA draft guidance suggested that the
composite Clinical Dementia Rating scale Sum-of-Boxes
score be used as the primary outcome measure in pivotal
clinical trials involving individuals with mild cognitive im-
pairment due to AD or prodromal AD [31,32]. Our AUC
4D-CI analysis, due to its ability to capture both the clin-
ical trajectory and a four-dimensional picture of illness,
should be investigated in future studies as a potential can-
didate outcome measure for inclusion in AD clinical trials.Conclusions
In summary, results from this large pooled AUC analysis
of randomized-trial data in moderate to severe AD provide
significant support that memantine add-on combin-
ation with donepezil provides benefits that are additive,
compared with benefits of individual monotherapies, and
that continue to accumulate over six months of treatment.
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